Published Date: 02 Mar 2023
The latest studies of long-acting ART show benefits even in people who are not immune. Meanwhile, early proof-of-concept results for twice-yearly injection are encouraging.
Read Full NewsHistorical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.
New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.
Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.
1.
New study elucidates obesity's role in fueling breast cancer progression
2.
For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.
3.
A study outlines the need for policies that enhance cancer patients' autonomy and information.
4.
The Truth About Apple AirPods
5.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
1.
The Digital Revolution in Oncology - How Software, AI, and Data are Reshaping Cancer Care by 2025
2.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
3.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
4.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
5.
Unraveling the Mysteries of Lymphoma: A Journey into the Unknown
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation